| Generic/working name | Atezolizumab |
| Company name | Chugai Pharmaceutical Co., Ltd. Roche Holding AG |
| Drug type | Anti-PD-L1 monoclonal antibody |
| Drug class | Antineoplastic agent |
| Dose | 1200 mg |
| Unit | mg |
| Route | i.v. |
| Schedule of administration | every 3 weeks |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.